drug combination
424 articles
Drug Combination to Combat Pancreatic and other Gastrointestinal Cancers
Researchers are testing a drug combination of TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, on gastrointestinal cancers.
Testing the Effectiveness of Immunotherapy Added to a New Drug Combination
Researchers are testing a drug combination that adds immunotherapy to standard drugs used to treat pancreatic cancer and an antimalarial drug.
Novel Drug Combination Plus Radiation for Locally Advanced Pancreatic Cancer
A clinical trial combines immunotherapy, common treatments, an antiretroviral drug, and SBRT for locally advanced pancreatic cancer.
A New Drug Combination to Control Advanced Pancreatic Cancer
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
Two-Drug Combo Targets KRAS and Fights Resistance
Researcher Hervé Tiriac leads a clinical trial for a new drug combination targeting KRAS and chemotherapy resistance.
A New Triple Combination for Tumors with BRCA1/2 or PALB2 Mutations
A clinical trial is comparing a two-drug combination with a three-drug combination to see which works better for genetic mutations.
Pancreatic Cancer Research Updates from ASCO 2024
Learn about the latest developments in pancreatic cancer research into immunotherapy and chemotherapy from the ASCO 2024 meeting.
A New Immunotherapy Combination for Metastatic Pancreatic Cancer
Researchers are looking at a combination of two types of monoclonal antibodies to treat advanced pancreatic cancer.
Pancreatic Cancer Research Builds Upon Strengths
The September 2023 AACR Special Conference on Pancreatic Cancer focused on the latest research in KRAS, chemotherapy, and cachexia, among other topics.
Testing Treatment Combinations to Make Surgery More Effective
Can losartan (a high blood pressure drug) and immunotherapy combined with standard chemotherapy and radiation be an effective combination against pancreatic cancer?
Drug Onivyde Gives New Hope to Patients with Advanced Pancreatic Cancer
Onivyde (injectable irinotecan), combined with fluorouracil and leucovorin, has been approved as a second-line treatment for advanced pancreatic cancer.
A Novel Combination to Slow Pancreas Tumors that Cannot Be Surgically Removed
Can a combination of standard drugs, a PARP inhibitor, and intensity modulated radiation therapy to slow pancreatic tumor growth?